Ardea Biosciences gets UK MHRA nod for phase II trial of HIV compound
Saturday, January 05, 2008 13:00 IST Carlsbad, California
Ardea Biosciences, Inc. disclosed that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has authorised a phase IIa clinical trial evaluating RDEA806